{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-017958","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.829624+00:00","generated_at":"2026-05-22T03:21:04.844201+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rocket Pharma Q1 net loss $61.3M; cash $318.2M; pipeline on track","bullets":["Net loss of $61.3M ($0.56/share) vs $62.1M in Q1 2024; R&D expenses down to $35.9M.","Cash, equivalents, investments $318.2M; operational runway into Q4 2026.","Phase 2 RP-A501 for Danon disease ongoing; program update mid-2025, data mid-2026.","Initial Phase 1 data for RP-A601 (PKP2-ACM) expected May 2025; IND for BAG3-DCM mid-2025.","Rolling BLA for RP-L102 (Fanconi Anemia); final module late 2025/early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-017958","json":"https://secwatch.observer/filing/0001140361-25-017958.json","markdown":"https://secwatch.observer/filing/0001140361-25-017958.md","text":"https://secwatch.observer/filing/0001140361-25-017958.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/0001140361-25-017958-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/ef20048651_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:21:04.844201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}